Jorge Avila, MD
Psychiatry · El Paso, TXNPI 1255538187
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Corium, LLC accounts for 77.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $2,607 and has fallen 83.8% since, to $422 in 2025.
Across 47 payments — averaging $78.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$3K
- Alkermes, Inc.$501
- Neurocrine Biosciences, Inc.$135
- E.r. Squibb & Sons, L.L.C.$62
- Sunovion Pharmaceuticals Inc.$58
- Ironshore Pharmaceuticals Inc.$30
- plus $41 from 2 others
Across 3 payments — averaging $11,410 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$34K
What the payments were for
- Consulting fees$36010%
- Speaking & faculty fees$1,68046%
- Food & beverage$1,63645%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 30 | $2,850 |
| Alkermes, Inc. | 7 | $501 |
| Neurocrine Biosciences, Inc. | 1 | $135 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Sunovion Pharmaceuticals Inc. | 3 | $58 |
| Ironshore Pharmaceuticals Inc. | 1 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azstarys$2,316
- ARISTADA$1,312
- ARISTADA INITIO$328
- INGREZZA$135
- VIVITROL$109
How this compares
$3,676 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 67 | $767 |
| Buspirone Hcl | 21 | $400 |
| Quetiapine Fumarate | 20 | $329 |
| Doxepin Hcl | 20 | $326 |
| Trazodone Hcl | 30 | $294 |
| Hydroxyzine Pamoate | 15 | $273 |
| Olanzapine | 16 | $267 |
| Duloxetine Hcl | 21 | $232 |
| Mirtazapine | 14 | $168 |
| Omeprazole | 19 | $160 |
| Propranolol Hcl | 11 | $131 |
| Fluoxetine Hcl | 14 | $84 |
| Levothyroxine Sodium | 13 | $84 |
| Lisinopril | 12 | $68 |
| Lamotrigine | 13 | $38 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in El Paso
- Martin GuerreroEl Paso$2M
- Aghaegbulam UgaEl Paso$93K
- Angel Rodriguez-ChevresEl Paso$82K
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.